Pr François Ghiringhelli

Specialty

Oncologist, digestive expert

Hospital

Centre Georges-François Leclerc (Dijon)

Latest articles

• Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. (Mar 13, 2026)
• Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. (Mar 3, 2026)
• Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights. (Feb 28, 2026)
• Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy. (Feb 13, 2026)
• The promise of IL-1β modulation in NSCLC clinical context. (Jan 30, 2026)